Entity Details

Primary name PTN22_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionQ9Y2R2
EntryNamePTN22_HUMAN
FullNameTyrosine-protein phosphatase non-receptor type 22
TaxID9606
Evidenceevidence at protein level
Length807
SequenceStatuscomplete
DateCreated2002-03-27
DateModified2021-06-02

Ontological Relatives

GenesPTPN22

GO terms

Show/Hide Table
GOName
GO:0002230 positive regulation of defense response to virus by host
GO:0004725 protein tyrosine phosphatase activity
GO:0004726 non-membrane spanning protein tyrosine phosphatase activity
GO:0005634 nucleus
GO:0005737 cytoplasm
GO:0005829 cytosol
GO:0006470 protein dephosphorylation
GO:0006914 autophagy
GO:0009898 cytoplasmic side of plasma membrane
GO:0010507 negative regulation of autophagy
GO:0010628 positive regulation of gene expression
GO:0010629 negative regulation of gene expression
GO:0016791 phosphatase activity
GO:0017124 SH3 domain binding
GO:0019900 kinase binding
GO:0030217 T cell differentiation
GO:0031625 ubiquitin protein ligase binding
GO:0031663 lipopolysaccharide-mediated signaling pathway
GO:0032481 positive regulation of type I interferon production
GO:0032496 response to lipopolysaccharide
GO:0032715 negative regulation of interleukin-6 production
GO:0032717 negative regulation of interleukin-8 production
GO:0032720 negative regulation of tumor necrosis factor production
GO:0032729 positive regulation of interferon-gamma production
GO:0032817 regulation of natural killer cell proliferation
GO:0034141 positive regulation of toll-like receptor 3 signaling pathway
GO:0034145 positive regulation of toll-like receptor 4 signaling pathway
GO:0034157 positive regulation of toll-like receptor 7 signaling pathway
GO:0034165 positive regulation of toll-like receptor 9 signaling pathway
GO:0035335 peptidyl-tyrosine dephosphorylation
GO:0035644 phosphoanandamide dephosphorylation
GO:0043508 negative regulation of JUN kinase activity
GO:0045088 regulation of innate immune response
GO:0048471 perinuclear region of cytoplasm
GO:0050852 T cell receptor signaling pathway
GO:0050855 regulation of B cell receptor signaling pathway
GO:0050860 negative regulation of T cell receptor signaling pathway
GO:0050868 negative regulation of T cell activation
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070433 negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway
GO:0071225 cellular response to muramyl dipeptide
GO:0071663 positive regulation of granzyme B production
GO:1901222 regulation of NIK/NF-kappaB signaling
GO:1902523 positive regulation of protein K63-linked ubiquitination
GO:1903753 negative regulation of p38MAPK cascade
GO:2000566 positive regulation of CD8-positive, alpha-beta T cell proliferation

Subcellular Location

Show/Hide Table
Subcellular Location
Cytoplasm

Domains

Show/Hide Table
DomainNameCategoryType
IPR000242 PTP type protein phosphataseDomainDomain
IPR000387 Tyrosine specific protein phosphatases domainDomainDomain
IPR003595 Protein-tyrosine phosphatase, catalyticDomainDomain
IPR016130 Protein-tyrosine phosphatase, active siteSiteActive site
IPR016276 Non-receptor tyrosine-protein phosphatase 22FamilyFamily
IPR029021 Protein-tyrosine phosphatase-likeFamilyHomologous superfamily

Diseases

Show/Hide Table
Disease IDSourceNameDescription
152700 OMIMSystemic lupus erythematosus (SLE)A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Disease susceptibility is associated with variants affecting the gene represented in this entry.
193200 OMIMVitiligo (VTLG)A pigmentary disorder of the skin and mucous membranes. It is characterized by circumscribed depigmented macules and patches, commonly on extensor aspects of extremities, on the face or neck and in skin folds. Vitiligo is a progressive disorder in which some or all of the melanocytes in the affected skin are selectively destroyed. It is a multifactorial disorder with a complex etiology probably including autoimmune mechanisms, and is associated with an elevated risk of other autoimmune diseases. Disease susceptibility is associated with variants affecting the gene represented in this entry.
180300 OMIMRheumatoid arthritis (RA)An inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Disease susceptibility is associated with variants affecting the gene represented in this entry.
222100 OMIMDiabetes mellitus, insulin-dependent (IDDM)A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. Disease susceptibility is associated with variants affecting the gene represented in this entry.